Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 May;15(5):519–527. doi: 10.1111/j.1365-2125.1983.tb02085.x

The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension.

M J Serlin, M L Orme, M MacIver, G J Green, R G Sibeon, A M Breckenridge
PMCID: PMC1427717  PMID: 6860527

Abstract

1 The effects on heart rate and blood pressure after single and multiple dosing (1 month) of a long acting formulation of propranolol 160 mg daily, and conventional propranolol, 80 mg twice daily, or 160 mg daily were compared in 11 moderately hypertensive subjects previously shown to respond to propranolol. 2 After acute dosing all three treatments produced significant reduction in blood pressure. After multiple dosing all three treatments maintained significant reductions in lying, standing and exercise heart rate and blood pressure throughout the 24 h. At 24 h, after multiple dosing, the fall in resting and standing systolic BP was significantly greater with LA propranolol than with conventional propranolol 80 mg twice daily or conventional propranolol 160 mg once daily (P at least less than 0.05). 3 The plasma propranolol concentration time curve after LA propranolol showed slowed absorption, and the area under the curve was significantly lower than after conventional propranolol (acute dosing; LA propranolol 160 mg 560 mg ml-1 h, conventional propranolol 80 mg twice daily 1135 mg ml-1 h, conventional propranolol 160 mg daily 1414 mg ml-1 h).

Full text

PDF
519

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. England J. D. Beta adrenoreceptor-blocking drugs once daily in essential hypertension: a comparison of propranolol, pindolol and atenolol. Aust N Z J Med. 1981 Feb;11(1):35–40. doi: 10.1111/j.1445-5994.1981.tb03733.x. [DOI] [PubMed] [Google Scholar]
  2. Gatley M. S. To be taken as directed. J R Coll Gen Pract. 1968 Jul;16(1):39–44. [PMC free article] [PubMed] [Google Scholar]
  3. Marshall A., Barritt D. W. Drug complience in hypertensive patients. Br Med J. 1977 May 14;1(6071):1278–1279. doi: 10.1136/bmj.1.6071.1278-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. McAinsh J., Baber N. S., Smith R., Young J. Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol. 1978 Aug;6(2):115–121. doi: 10.1111/j.1365-2125.1978.tb00835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Prichard B. N., Gillam P. M. Treatment of hypertension with propranolol. Br Med J. 1969 Jan 4;1(5635):7–16. doi: 10.1136/bmj.1.5635.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Serlin M. J., Orme M. L., Baber N. S., Sibeon R. G., Laws E., Breckenridge A. Propranolol in the control of blood pressure: a dose-response study. Clin Pharmacol Ther. 1980 May;27(5):586–592. doi: 10.1038/clpt.1980.83. [DOI] [PubMed] [Google Scholar]
  7. Shand D. G., Nuckolls E. M., Oates J. A. Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):112–120. doi: 10.1002/cpt1970111112. [DOI] [PubMed] [Google Scholar]
  8. van den Brink G., Boer P., van Asten P., Dorhout Mees E. J., Geyskes G. G. One and three doses of propranolol a day in hypertension. Clin Pharmacol Ther. 1980 Jan;27(1):9–15. doi: 10.1038/clpt.1980.2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES